Bayer Schering Pharma is one of the world’s leading, innovative companies in the healthcare and medical products industry. Bayer Schering Pharma’s oncology business unit includes a global group of dedicated individuals working to develop solutions that improve the lives of cancer patients.
Through compassion and collaboration, Bayer continues to discover new treatments to help improve the health of cancer patients worldwide. Bayer Schering Pharma’s research efforts have resulted in a balanced, diverse portfolio of potential cancer therapies. The Company is proud to contribute to liver cancer research, development and education through support of the International Liver Cancer Association.
Biocompatibles International plc is a medical technology company focused ondrug-device combination products principally for use in oncology.Biocompatibles’ Drug-Eluting Bead, DC Bead, is used in the treatment ofhepatocellular (liver) cancer and hepatic colorectal metastases. Ourstrategic partners include Terumo Corporation, AngioDynamics and SciClonePharmaceuticals.
Sirtex Medical Europe GmbH is a wholly owned subsidiary of Sirtex Medical Pty Ltd, a publicly listed company on the Australian Exchange engaged in the field of oncology and interventional oncology. SIR-Spheres microspheres is presently employed in the treatment of a variety of unresectable metastatic liver tumors as well as in Hepatocellular Carcinoma at numerous institutions within Europe including Austria, Belgium, Germany, Italy, Spain, Sweden, Switzerland and United Kingdom. Outside of the European Union, SIR-Spheres microspheres is employed in Asia-Pacific and the Middle East, and is approved in the US for the treatment of unresectable colorectal liver metastases.
As a world-leading supplier of radiation technologies, MDS Nordion will be promoting our liver cancer treatment TheraSphere. A Yttrium-90 glass microspheres treatment, it is used in radiation treatment or as a bridge to surgery or transplantation. It is an intra-arterial, minimally-embolic therapy providing an approved treatment option of portal vein thrombosis patients, improved quality of life and re-treatment potential.